Psychiatry · Medical Literature
[Correspondence] Communication, expectancy, and placebo response in clinical trial design
Abstract
The Review by Matthew J Burke and colleagues1 highlights the growing recognition that placebo and nocebo effects are biologically grounded phenomena capable of meaningfully influencing clinical outcomes. Burke and colleagues’ synthesis reflects an important shift away from viewing placebo responses as nuisance variables towards recognising them as mechanistic processes involving dopaminergic, opioid, and salience-related neural systems. Such responses are particularly relevant in conditions characterised by subjective symptoms and fluctuating trajectories, where expectations and contextual cues might influence outcomes.
Clinical relevance
Do communication style, patient expectancy, and contextual cues within clinical trial design meaningfully modulate placebo and nocebo responses in psychiatric populations, and should these phenomena be reframed from nuisance variables into mechanistically tractable targets? __SNAPSHOT__ {"studyDesign":"Correspondence (letter to the editor) responding to a published review article; no original empirical data collected","setting":"Not applicable (editorial correspondence published in The Lancet Psychiatry, June 2026)","sampleSize":"Not applicable; no primary dataset","population":"Not applicable; commentary addresses patients enrolled in psychiatric clinical trials broadly, particularly those with conditions characterised by subjective symptoms and fluctuating clinical trajectories","intervention":"The correspondence discusses communication strategies, expectancy framing, and contextual cues as potential modulators of placebo and nocebo responses within trial design","comparator":"Not applicable; no experimental comparator","primaryOutcome":"Not applicable; no primary outcome measure defined","followUp":"Not applicable","fundingSource":"Not reported"}
Key findings
This correspondence contains no original quantitative data, effect sizes, p-values, confidence intervals, or primary outcome results. The authors affirm and extend the thesis of the Burke et al. review (Lancet Psychiatry, 2026, Vol. 13, pp. 413–425), which itself documents that placebo-group remission rates in novel psychiatric device trials have approached 50% — a figure referenced from the parent review, not independently reported by these correspondents. The correspondents argue that placebo and nocebo effects are biologically grounded, involve dopaminergic, opioid, and salience-related neural systems, and are especially potent in conditions with subjective symptomatology and fluctuating courses. No NNT, NNH, or any calculated statistic is derivable from this correspondence alone.
Practice implications
This correspondence does not establish new clinical evidence; it synthesises and contextualises arguments from the Burke et al. two-part Lancet Psychiatry review series on reconceptualising placebo and nocebo effects. What is reinforced — though not proven by this letter — is that placebo and nocebo responses should be understood as neurobiologically mediated processes involving dopaminergic and opioidergic signalling, not as statistical noise to be minimised. The parent review highlights that in psychiatric device trials, placebo-arm remission rates have approached 50%, raising fundamental questions about how expectancy, therapeutic context, and clinician communication shape measured outcomes. The correspondence specifically draws attention to trial design as a locus of modifiable expectancy — i.e., how participants are informed, randomised, and communicated with may itself constitute an active ingredient shaping biological response. These insights apply most directly to conditions with high subjectivity (e.g., major depressive disorder, anxiety disorders, functional neurological disorders) and less clearly to conditions with more objective biomarker endpoints. Critically, the correspondence is limited to abstract-level content only; no empirical data, methodology, or statistical analysis is presented. Clinicians should not interpret this as prescriptive guidance but as a conceptual argument warranting prospective investigation. Practice change on the basis of this letter alone is not warranted. __LIMITATIONS__ This is a correspondence piece, not an original research study; it generates no new empirical evidence.,Only the abstract is publicly available; the full text of the correspondence was not accessible for this summary, which limits comprehensive appraisal.,No primary data, statistical analysis, patient-level data, or systematic methodology is employed.,The biological mechanisms cited (dopaminergic, opioidergic, salience systems) are supported by the broader placebo neuroscience literature but are not tested or quantified within this correspondence.,The scope of applicability across psychiatric diagnostic categories is not systematically defined.,No conflict of interest disclosures or funding sources are reported within the abstract.,As a letter responding to a review, the arguments are inherently constrained by the scope and conclusions of the parent review; independent verification is not provided.,Generalisability to non-psychiatric medical conditions, paediatric populations, or low-resource settings is not addressed. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This correspondence affirms a conceptual shift — supported by the broader Lancet Psychiatry review series — toward viewing placebo and nocebo effects as neurobiologically active, mechanistically relevant phenomena rather than methodological confounds. Clinicians should be aware that communication style, expectancy framing, and trial context may meaningfully influence psychiatric outcomes, particularly in conditions driven by subjective symptoms. No practice change is warranted from this letter alone; however, it underscores the importance of future trial designs that systematically measure and account for expectancy as a biological variable.